Navrogen, Inc, a privately held preclinical biotechnology company, announced on Monday that it has signed a Cooperative Research and Development Agreement with researchers at The United States Army Medical Research Institute of Infectious Diseases.
The Cooperative Research and Development Agreement intends to test Navrogen's small molecule NK cell activating agents on suppressing propagation of SARS-COV-2. Researchers at The United States Army Medical Research Institute of Infectious Diseases have produced model systems to test agents capable of suppressing SARS-COV-2 infection and propagation. Navrogen has assembled a range of compounds that are able to activate human and rodent NK cells to stimulate humoral immune responses to deal with dysregulated cells.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval